Investigated
Could increasing UBE2N activity prevent progression from fatty liver to MASH?
Short answer
Image: cedars-sinai.org
Preclinical evidence suggests that increasing liver UBE2N activity could reduce progression toward MASH by improving removal of damaged mitochondria and limiting inflammatory cell death. However, the evidence currently comes from human samples and mouse models, not clinical trials, so it does not establish that raising UBE2N activity will prevent MASH in people.
The views on this question
Two lenses on the same evidence. Source weight and the primary source ratio show what each rests on.
Alternative
Source weight 43%Lens adapted to this topic: Limits and open questions
A cautious interpretation emphasizes that the evidence does not yet show that increasing UBE2N activity prevents fatty liver from becoming MASH in humans. The available reports describe mechanistic and animal findings, while treatment feasibility, dosage, tissue specificity, long-term safety, and clinical effectiveness remain open questions.
- The central evidence is from hepatocyte-specific mouse models and associated human samples, not a reported human intervention trial.
- Improving UBE2N activity may affect several interconnected pathways, including mitophagy, p62 accumulation, NRF2 signaling, and PANoptosis, making targeted treatment effects difficult to predict.
- The available reports identify a potential therapeutic direction, but they do not establish that UBE2N activation alone prevents progression from fatty liver to MASH.
- Current MASH management still focuses on lifestyle changes and protecting the liver from further damage, with limited effective medication options noted in the reports.